Sanofi $SNY Shares Sold by Brucke Financial Inc.

Brucke Financial Inc. cut its stake in Sanofi (NASDAQ:SNY) by 6.4% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 8,326 shares of the company’s stock after selling 566 shares during the period. Brucke Financial Inc.’s holdings in Sanofi were worth $402,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors also recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. boosted its stake in Sanofi by 124.0% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 24,131 shares of the company’s stock worth $1,344,000 after purchasing an additional 13,358 shares in the last quarter. Axxcess Wealth Management LLC lifted its stake in Sanofi by 130.5% during the 1st quarter. Axxcess Wealth Management LLC now owns 10,234 shares of the company’s stock valued at $568,000 after acquiring an additional 5,794 shares during the period. Ballentine Partners LLC lifted its stake in Sanofi by 68.7% during the 1st quarter. Ballentine Partners LLC now owns 26,063 shares of the company’s stock valued at $1,445,000 after acquiring an additional 10,617 shares during the period. Voya Investment Management LLC lifted its stake in Sanofi by 11.6% during the 1st quarter. Voya Investment Management LLC now owns 206,635 shares of the company’s stock valued at $11,460,000 after acquiring an additional 21,540 shares during the period. Finally, Sowell Financial Services LLC acquired a new stake in Sanofi during the 1st quarter valued at approximately $328,000. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have commented on the stock. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Tuesday, September 2nd. Morgan Stanley upgraded shares of Sanofi from an “equal weight” rating to an “overweight” rating and lifted their price objective for the company from $56.00 to $58.00 in a research note on Monday, September 8th. Wall Street Zen upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a research note on Saturday, August 2nd. JPMorgan Chase & Co. upgraded shares of Sanofi from a “neutral” rating to an “overweight” rating in a research note on Friday, August 8th. Finally, Barclays restated an “overweight” rating on shares of Sanofi in a research note on Wednesday, July 2nd. Two analysts have rated the stock with a Strong Buy rating, six have given a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, Sanofi has an average rating of “Buy” and a consensus target price of $62.67.

Sanofi Price Performance

NASDAQ:SNY opened at $48.09 on Friday. The company has a debt-to-equity ratio of 0.19, a current ratio of 1.27 and a quick ratio of 0.94. The firm has a market cap of $118.09 billion, a price-to-earnings ratio of 11.56, a price-to-earnings-growth ratio of 1.19 and a beta of 0.51. The company has a 50 day moving average price of $48.27 and a 200-day moving average price of $49.82. Sanofi has a 1-year low of $44.62 and a 1-year high of $60.12.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, July 31st. The company reported $0.90 earnings per share for the quarter, missing the consensus estimate of $0.96 by ($0.06). The firm had revenue of $11.34 billion for the quarter, compared to analysts’ expectations of $9.91 billion. Sanofi had a net margin of 21.47% and a return on equity of 16.86%. Sanofi’s revenue for the quarter was down 7.0% compared to the same quarter last year. During the same period last year, the firm earned $1.73 earnings per share. Equities research analysts forecast that Sanofi will post 4.36 EPS for the current year.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.